Payment overview · 2025
General Payments
$494.41
29 reported records · 8 companies
Healthcare provider profile · identity verified
Fred A. Hurst, MD
Allopathic & Osteopathic Physicians|Family Medicine · KNOXVILLE, TN · NPI 1700821949
Verified facts
What the public records show
CMS Open Payments records show Fred A. Hurst, MD received $494.41 in general payments during 2025 across 29 reported records.
ABBVIE INC. accounted for 39.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $197.09 | 39.9% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $121.33 | 24.5% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.50 | 12.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $45.22 | 9.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.10 | 4.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.90 | 3.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.68 | 3.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.59 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $494.41 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $121.33 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.82 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.27 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $81.03 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $61.50 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.35 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
91 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 552 | 146 |
| Simvastatin | Simvastatin | 371 | 108 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 103 |
| Gabapentin | Gabapentin | 343 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 281 | 77 |
| Glimepiride | Glimepiride | 275 | 74 |
| Omeprazole | Omeprazole | 267 | 76 |
| Famotidine | Famotidine | 262 | 90 |
| Alprazolam | Alprazolam | 230 | 47 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 195 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 52 |
| Furosemide | Furosemide | 161 | 51 |
| Lisinopril | Lisinopril | 159 | 44 |
| Potassium Chloride | Potassium Chloride | 143 | 47 |
| Metformin Hcl Er | Metformin Hcl | 139 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 36 |
| Meloxicam | Meloxicam | 123 | 39 |
| Jardiance | Empagliflozin | 116 | 24 |
| Metformin Hcl | Metformin Hcl | 109 | 32 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 107 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 24 |
| Propranolol Hcl | Propranolol Hcl | 106 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 103 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 53 |
| Celecoxib | Celecoxib | 102 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 72 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 28 |
| Tramadol Hcl | Tramadol Hcl | 95 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 18 |
| Buspirone Hcl | Buspirone Hcl | 94 | 30 |
| Eliquis | Apixaban | 91 | 23 |
| Losartan Potassium | Losartan Potassium | 90 | 25 |
| Allopurinol | Allopurinol | 87 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 27 |
| Meclizine Hcl | Meclizine Hcl | 83 | 40 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 21 |
| Prednisone | Prednisone | 78 | 49 |
| Benazepril Hcl | Benazepril Hcl | 76 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 23 |
| Montelukast Sodium | Montelukast Sodium | 76 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 25 |
| Trazodone Hcl | Trazodone Hcl | 74 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 22 |
| Spironolactone | Spironolactone | 70 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 69 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 69 | 25 |
| Atenolol | Atenolol | 60 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 53 | 15 |
| Diazepam | Diazepam | 50 | suppressed |
| Lovastatin | Lovastatin | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Azithromycin | Azithromycin | 43 | 33 |
| Donepezil Hcl | Donepezil Hcl | 43 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 43 | 11 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Amoxicillin | Amoxicillin | 42 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 12 |
| Januvia | Sitagliptin Phosphate | 40 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Ondansetron Odt | Ondansetron | 40 | 12 |
| Cephalexin | Cephalexin | 39 | 28 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 30 |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 31 |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Cefdinir | Cefdinir | 33 | 26 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | 12 |
| Colchicine | Colchicine | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 18 |
| Ozempic | Semaglutide | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 15 |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Pregabalin | Pregabalin | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Captopril | Captopril | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Bumetanide | Bumetanide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nexium | Esomeprazole Magnesium | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $494.41 · 29 records | ABBVIE INC. | FREESTYLE LIBRE 3, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error